Press release
The antibody drug conjugates market is estimated to be worth USD 23.3 billion in 2035, predicts Roots Analysis
To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/antibody-drug-conjugates-market/request-quote.html
The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies. Amongst other elements, the report includes:
1. A detailed assessment of the market landscape of close to 400 antibody drug conjugates / ADC therapeutics that are either approved or being evaluated in different stages of development
2. An insightful competitiveness analysis of biological targets, featuring insightful pictorial summaries and representations.
3. Elaborate profiles of leading antibody drug conjugate companies (shortlisted based on sales revenue of 2022) and their respective product portfolios.
4. An in-depth analysis of completed, ongoing, and planned clinical studies of various antibody drug conjugates
5. An insightful analysis, highlighting the key opinion leaders (KOLs) investigating clinical trials related to antibody drug conjugates
6. An assessment of various therapeutics that are being evaluated in combination with antibody-drug conjugates.
7. A detailed analysis of partnerships established by stakeholders engaged in this industry, since 2014
8. An analysis of the various funding and investments made in the ADC domain, in the recent past
9. An in-depth analysis of the various patents that have been filed / granted related to antibody drug conjugates
10. A study of the various grants that have been awarded to research institutes engaged in conducting research related to antibody drug conjugates, since 2016
11. An elaborate discussion on commercialization strategies adopted by various drug developers for their respective products
12. An analysis of the key promotional strategies that have been adopted by the developers of marketed products
13. An insightful success protocol analysis of recently approved ADC therapeutics, based on several relevant parameters
14. An overview on of various conjugation and linker technologies along with their types that are presently being employed in the designing and development of antibody drug conjugates
15. An overview of the studies conducted to better analyze non-clinical data and support first-in-human (FIH) dose selection in antibody drug conjugates
16. An elaborate discussion on various factors that form the basis for the pricing of antibody drug conjugate products
17. A case study on manufacturing of antibody drug conjugates, highlighting the key challenges, and a list of contract service providers that are involved in the ADC market.
18. A case study on companies offering companion diagnostics that can potentially be used to make treatment related decisions involving antibody-drug conjugates
19. A discussion on affiliated trends, key drivers, and challenges, under a comprehensive SWOT framework, which are likely to impact the industry's evolution
20. A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Target Disease Indication
1. Acute Lymphoblastic Leukemia
2. Breast Cancer
3. B-Cell Lymphoma
4. Cervical Cancer
5. Gastric Cancer
6. Lung Cancer
7. Multiple Myeloma
8. Renal Cancer
9. Other Target Disease Indications
Therapeutic Area
1. Hematological Cancer
2. Solid Tumor
To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/antibody-drug-conjugates-market/request-sample.html
Linker
1. Hydrazone (4-(4-Acetylphenoxy) Butanoic Acid (Acbut)
2. Maleimide
3. Maleimidocaproyl
4. Succinimidyl-4-(N-Maleimidomethyl) Cyclohexane-1-Carboxylate
5. Tetrapeptide-Based Linker
6. Valine-Alanine
7. Valine-Citrulline
8. Other Linkers
Payload
1. DM1
2. DM4
3. Duocarmycin
4. Monomethyl auristatin E (MMAE)
5. Monomethyl auristatin F (MMAF)
6. Ozogamicin
7. SG3199
8. SN-38 / Irinotecan
9. Other Payloads
Target Antigen
1. BCMA (TNFRSF17 / BCM)
2. CD19
3. CD22
4. CD30
5. CD79b
6. CEACAM5
7. HER-2 (ERBB2)
8. Nectin 4
9. Tissue factor
10. TROP-2
11. Other Target Antigen
Key Geographical Regions
1. North America
2. Europe
3. Asia-Pacific and Rest of the World
Key companies covered in the report
1. ADC Therapeutics
2. Astellas Pharma
3. AstraZeneca
4. Byondis
5. Daiichi Sankyo
6. Genentech
7. Gilead Sciences
8. ImmunoGen
9. Pfizer
10. RemeGen
Browse Full Report Description + Research Methodology + Table of Content + Infographics here: https://www.rootsanalysis.com/reports/antibody-drug-conjugates-market/270.html
Contact:
Gaurav Chaudhary
gaurav.chaudhary@rootsanalysis.com
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The antibody drug conjugates market is estimated to be worth USD 23.3 billion in 2035, predicts Roots Analysis here
News-ID: 4091572 • Views: …
More Releases from Roots Analysis
T-Cell Therapy Market Size to Hit USD 20.9 billion by 2035| Exclusive Report by …
Cancer is one of the leading causes of mortality across the world. As per the International Agency for Research on Cancer (IARC), by 2040, there are likely to be 27.5 million new cases and 16.3 million deaths related to cancer, annually. Although cancer therapeutics continue to be one of the most active areas, in terms of drug development, there is still a significant unmet need in this domain. In fact,…
Cancer Biologics Market: Unmet Need and Treatment Guidelines
Owing to the increasing mortality rates and growing need for novel modalities to treat oncological disorders, several researchers and industry stakeholders have shifted their focus on the development of safe and effective biologic therapies. Cancer biologics are the class of therapeutic agents, which primarily modulate immune responses or directly inhibits oncogenic pathways in malignancies. These therapies, such as monoclonal antibodies, specifically target tumor-activating genes, facilitate antibody-dependent cellular cytotoxicity and complement…
Peptide Synthesis: Supporting Next Generation Targeted Therapies
Peptides are specialized molecules composed of short chains of amino acids and are used primarily as the active ingredients in a new class of targeted therapeutics. Peptide synthesis is achieved through various advanced methodologies, including chemical processes like solid-phase (SPPS) and liquid-phase (LPPS), as well as hybrid and non-chemical approaches.
Peptides are being extensively used as therapeutics to treat various disorders, including metabolic diseases, oncological disorders, and hormonal imbalances due to…
Prefilled Syringes Market Size to Hit USD 4.97 billion by 2035| Exclusive Report …
Prefilled syringes: setting new standards for safe and efficient drug administration. With the increasing population, the incidence rates of various chronic diseases, such as diabetes, autoimmune disorders, cardiovascular disorders and oncological disorders, are witnessing an upward trend.
The global prefilled syringes market, valued at USD 3.02 billion in 2024, is project to reach USD 3.19 billion in 2025 and USD 4.97 billion by 2035, representing a CAGR of 4.5% during the…
More Releases for ADC
ADC Market: Transforming Cancer Treatment
The global market for antibody-drug conjugates (ADCs) was valued at US$ 11.32 billion in 2023 and is expected to reach US$ 27.37 billion by 2033, growing at a compound annual growth rate (CAGR) of 9.23% from 2024 to 2033. This growth is primarily driven by the increasing prevalence of cancer and the growing demand for safe and effective treatments.
Antibody Drug Conjugates: A Growing Force in Cancer Treatment and Market Expansion
Key…
With Knockout ADC Innovations, Creative Biolabs Took Center Stage at the 2024 Wo …
Creative Biolabs wrapped up a successful show at the 15th Annual World ADC San Diego in the beginning of November, where its third year of participation, highlighting its dedication to the advancement of antibody-drug conjugate (ADC) technology.
New York, USA - November 13, 2024 - Creative Biolabs seized the spotlight at Booth 313 by offering groundbreaking solutions across the entire ADC development spectrum, which demonstrate their unrivaled expertise and dedication to…
Showing Off Their ADC Game: Creative Biolabs Hits the 15th Annual World ADC Summ …
From November 4, Creative Biolabs will be back at the 15th Annual World ADC Summit in San Diego, marking its fourth year at the leading global gathering featuring innovative conjugates.
New York, USA - November 6, 2024 - Creative Biolabs invites all ADC enthusiasts, from new entrants to seasoned experts, to explore its comprehensive suite of ADC solutions and experience the latest in antibody-drug conjugate (ADC) innovation at Booth #313.
Image: https://www.getnews.info/uploads/0c59d26f78bf6dd58aafee5bc68d7d8c.jpg
"2023…
ADC Drugs For Breast Cancer Treatment
Breast cancer is the malignant tumor with the highest morbidity and mortality among women worldwide. At present, the main therapeutic methods include surgery, chemotherapy, radiotherapy, endocrine therapy and targeted therapy, etc. The development and marketing of new drugs have far-reaching significance in improving the survival of breast cancer patients and changing the pattern of breast cancer treatment.
On February 24, 2023, The NMPA approved Enhertu, an injectable drug developed jointly by…
Analog-to-Digital Converters Market by Product (Ramp ADC, Integrating ADC, Succe …
Analog-to-Digital Converters Market by Product (Ramp ADC, Integrating ADC, Successive Approximation ADC, Delta-sigma ADC, and Others (Pipelined/Flash ADC)), and Application (Consumer Electronics and Industrial) - Global Opportunity Analysis and Industry Forecast, 2017-2023
Full Report : https://www.alliedmarketresearch.com/analog-to-digital-converters-market
Increasing disposable income and technological advancements supplement the analog-to-digital converters market. However, complex design of the ADC hampers this market growth. On the other hand, encouragement in digitization of work processes by government in emerging economies,…
Global Data Converters Market Report 2017 (Analog to Digital Converter, Current …
The research report titled Global Data Converters Sales Market Report 2017 market size and forecast and overview on current market trends.
This report studies sales (consumption) of Global Data Converters Market 2017, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering
National Semiconductor
Nippon Precision Circuits Inc
Micro Analog systems
Microchip Technology.
TelCom Semiconductor, Inc
Vishay Siliconix
Texas…
